Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Evobrutinib (Primary) ; Dimethyl fumarate
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA
- 13 Oct 2023 Results evaluating comprising vitality (VT) and mental health, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
- 13 Oct 2023 Results from OLE, evaluating the long-term treatment effect of EVO on efficacy , presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 11 Oct 2023 Results published in the EMD Serono Media Release